Latest News
Adcentrx Therapeutics' ADRX-0405 granted Chinese regulatory IND clearance to treat late-stage solid tumours
9 June 2026 - Adcentrx Therapeutics, a California-based clinical-stage biotechnology company advancing Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, announced on Monday that the China National Medic...
Galmed Pharmaceuticals to acquire Colospan for GI-focused platform development
9 June 2026 - Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), an Israeli pharmaceutical company, announced on Monday that it has entered into a definitive agreement to acquire Colospan Ltd., an Israeli commercial-stage medical device company that is clai...
Argo Biopharma to present updated BW-20805 Phase II results at EAACI 2026 Congress
9 June 2026 - Argo Biopharmaceutical Co., Ltd., a China-based, clinical-stage small interfering RNA (siRNA) therapeutics company, announced on Monday that it has been selected to present Phase II updated results for BW-20805 at the European Associati...
Curasight reports encouraging preliminary Phase 1 data for uTREAT in glioblastoma
...
Alvotech reports FDA review acceptance for Entyvio biosimilar candidate AVT16
8 June 2026 - Global biotechnology company Alvotech S.A. (NASDAQ:ALVO) announced on Monday that the US Food and Drug Administration (FDA) has accepted for review its Biologics License Application for AVT16, a proposed interchangeable biosimilar to En...